New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2013
12:45 EDTCYH, POT, IPI, AGU, HLF, COH, MRK, PFE, AET, OSK, WU, PBI, HMA, MOSOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday as a report on rising home prices along with some better than expected earnings reports supported the market. The second quarter earnings season, which is reaching its peak this week, may not be turning out to be as bad as some had feared. However, the week's biggest events may still be yet to come, as investors brace for tomorrow's conclusion of the Fedís two day FOMC meeting, along with the latest monthly jobs report, due Friday. ECONOMIC EVENTS: In the U.S., the S&P/Case-Shiller 20-city home-price index was up 12.2% from the prior year and was up about 1.0% from the prior month in May, which was close to in line with forecasts. The consumer confidence index for July fell to 80.3, which was a bit worse than the expectation for it to slip just slightly from its prior reading of 81.4. COMPANY NEWS: Several of the day's worst performing stocks were fertilizer companies after Russian potash producer Uralkali ended its cooperation with Belarus' Belaruskali. Following the news, Potash (POT) tumbled 20%, Mosaic (MOS) plunged 19%, Intrepid Potash (IPI) plummeted 30%, and Agrium (AGU) dropped nearly 5%... Among several notable healthcare names to announce quarterly results this morning, Pfizer (PFE) performed the best, rising almost 1% following its report. Its peer, Merck (MRK), slid about 1% after its own report, while health insurer Aetna (AET) was little changed in midday trade. MAJOR MOVERS: Among the notable gainers following their earnings reports were Oshkosh (OSK), up 12%, Pitney Bowes (PBI), up 11%, and Western Union (WU), up 9%. Shares of multi-level marketer Herbalife (HLF) also rose over 4% following its report in spite of new questions from Bill Ackman's Pershing Square, which has a very large and well documented short position in the stock. Among the noteworthy losers was upscale accessories maker Coach (COH), which fell more than 7% after the company reported mixed fourth quarter results, announced the departure of two senior executives, and agreed to sell its Reed Krakoff business. Also lower were shares of hospital chain Health Management Associates (HMA), which fell 11% after Community Health (CYH) agreed to buy the company for the equivalent of about $13.78 per share plus possible future considerations based on the outcome of certain legal matters. INDICES: Near noon, the Dow was up 10.37, or 0.07%, to 15,532.34; the Nasdaq was up 23.81, or 0.66%, to 3,622.95; and the S&P 500 was up 3.18, or 0.19%, to 1,688.51.
News For CYH;HMA;PBI;WU;OSK;AET;PFE;MRK;COH;HLF;AGU;IPI;POT;MOS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 21, 2014
18:33 EDTHLFIcahn reiterates view that high-yield market is a bubble
Says the Fed has given the economy, or the patient, "too much medicine." Says market should not be shorted. Again, says Apple (AAPL) CEO Tim is a "great CEO." Says Apple pay has a great future. Says Ebay (EBAY) is like his past campaign at Motorola. Reiterates view that Ebay should explore Paypal sale right now. Says Dell is on his radar screen. Says Warren Buffet sometimes too easy on companies, should do more on corporate governance. Again, says has never sold a share of Herbalife (HLF). Says Western Europe has "major problems," and continues to be short the Euro. Says energy stocks "getting cheap." Carl Icahn is speaking on Bloomberg TV.
09:54 EDTPBIPitney Bowes implments go-to-market changes, focuses product offerings
Subscribe for More Information
07:15 EDTPFEFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:06 EDTPFEFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
11:00 EDTHLFHerbalife volatility increases
Subscribe for More Information
09:32 EDTMOSMosaic upgraded to Outperform from Sector Perform at Scotia Capital
Subscribe for More Information
08:58 EDTMOSPartnerRe to provide $100M financing for Mosaic's home solar loan program
Subscribe for More Information
08:48 EDTHLFHerbalife initiated with a Buy at Pivotal Research
Subscribe for More Information
08:06 EDTMRKMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:47 EDTPFEPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:34 EDTMRKAdvaxis names Mauro Chief Medical Officer
Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.
07:19 EDTMRKIBC Life Sciences to hold a conference
Subscribe for More Information
07:15 EDTPFEAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFE, MRKAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
05:54 EDTHLFStocks with implied volatility movement; HLD SD
Stocks with implied volatility movement; Herbalife (HLF) 109, SandRidge Energy (SD) 97 according to iVolatility.
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
07:58 EDTMRKDeutsche Bank specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gilbert provides of preview of The Improved Reduction of Outcomes: Vytorin Efficacy Internal Study (IMPROVE-IT) on an Analyst/Industry conference call to be held on October 17 at 10 am.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use